Johnson & Johnson (NYSE:JNJ) kick-started earnings for the sector with strong quarterly results, buoyed by COVID vaccine revenues. The stock also benefited from the Food and Drug Administration's emergency use authorization for its COVID booster shot. The drug regulator authorized Moderna, Inc. (NASDAQ:MRNA)'s booster dose, as well.

In another positive development, the FDA gave its green light for the use of mix-and-match vaccine regimen, i.e. allowing the use of either Moderna, Pfizer, Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) or J&J booster shots following the administration of another approved vaccine as the primary series.

Ventyx Biosciences, Inc. (NASDAQ:VTYX), Minerva Surgical, Inc. (NASDAQ:UTRS) and Context Therapeutics Inc. (NASDAQ:CNTX) were among the healthcare initial public offerings that were priced during the week.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has a tryst with the FDA this week, as the regulator is scheduled to rule on the company's supplemental NDA for purified Cortrophin gel, a purified adrenocorticotropic hormone, for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. The decision is expected by the PDUFA date of Friday, Oct. 29.

The FDA is also expected to announce by Saturday, Oct. 30 its verdict on Clearside Biomedical, Inc. (NASDAQ:LSD) & Bausch Health Companies Inc. (OTC:BHC)'s NDA for Xipere (triamcinolone acetonide) as a treatment option for macular edema associated with uveitis.

Nanobiotix S.A. (NASDAQ:NBTX): Updated data from Study 1100, a phase 1 basket study evaluating NBTXR3 activated by radiotherapy in combination with Bristol-Myers Squibb (NYSE:BMY)'s Opdivo or Merck & Co., Inc. (NYSE:MRK)'s Keytruda in locoregional recurrent or recurrent metastatic head & neck squamous cell carcinoma (Tuesday, Oct. 25, at 5 pm); Phase 1 study of NBTXR3, in combination with Opdivo and Keytruda in advanced cancer patients (Tuesday, Oct. 25, 5 pm), data from the Phase 1 Study of NBTXR3 in locally advanced HNSCC patients (Oct. 26, at 2:15 pm)

Thermo Fisher Scientific Inc. (NYSE:TMO) (before the market open)
Genocea Biosciences, Inc. (NASDAQ:GNCA) (before the market open)
Boston Scientific Corporation (NYSE:BSX) (before the market open)
Alkermes plc (NASDAQ:ALKS) (before the market open)
Bristol-Myers Squibb (before the market open)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the close)
Edwards Lifesciences Corporation (NYSE:EW) (after the close)

Merck (before the market open)
Evelo Biosciences, Inc. (NASDAQ:EVLO) (before the market open)
Baxter International Inc. (NYSE:BAX) (before the market open)
NovoCure Limited (NASDAQ:NVCR) (before the market open)
Repligen Corporation (NASDAQ:RGEN) (before the market open)
Blueprint Medicines Corporation (NASDAQ:BPMC) (before the market open)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (before the market open)
Laboratory Corporation of America Holdings (NYSE:LH) (before the market open)
Alimera Sciences, Inc. (NASDAQ:ALIM) (before the market open)
Bio-Rad Laboratories, Inc. (NYSE:BIO) (after the close)
PTC Therapeutics, Inc. (NASDAQ:PTCT) (after the close)
Merit Medical Systems, Inc. (NASDAQ:MMSI) (after the close)
LeMaitre Vascular, Inc. (NASDAQ:LMAT) (after the close)
Travere Therapeutics, Inc. (NASDAQ:TVTX) (after the close)
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (after the close)
ResMed Inc. (NYSE:RMD) (after the close)
CareDx, Inc (NASDAQ:CDNA) (after the close)

AbbVie Inc. (NYSE:ABBV) (before the market open)
ImmunoGen, Inc. (NASDAQ:IMGN) (before the market open)
IRadimed Corporation (NASDAQ:IRMD) (before the market open)

Princeton, New Jersey-based LianBio (NASDAQ:LIAN) has filed a preliminary prospectus with the SEC to offer 20.3125 million ADSs (American Depository Shares), representing 20.3125 million ordinary shares at an estimated price range of $15 and $17. The biopharma dedicated to developing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets, expects to list its shares on the Nasdaq under the ticker symbol "LIAN."
Aesthetic medical device company Candela Medical, Inc. is proposing to offer 14.71 million shares in an IPO. The Marlborough, Massachusetts-based company expects to price the offering between $16 and $18. The shares will likely begin trading on the Nasdaq under the ticker symbol "CDLA."
IPO Quiet Period Expiry